These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 15994755

  • 1. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
    Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD.
    Eur J Endocrinol; 2005 Jul; 153(1):135-41. PubMed ID: 15994755
    [Abstract] [Full Text] [Related]

  • 2. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
    Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD.
    J Endocrinol Invest; 2005 Jul; 28(11 Suppl International):21-7. PubMed ID: 16625841
    [Abstract] [Full Text] [Related]

  • 3. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [Abstract] [Full Text] [Related]

  • 4. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P.
    Neuroendocrinology; 2006 Jan; 83(3-4):258-63. PubMed ID: 17047391
    [Abstract] [Full Text] [Related]

  • 5. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.
    Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5545-52. PubMed ID: 12466351
    [Abstract] [Full Text] [Related]

  • 6. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
    Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH.
    J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
    [Abstract] [Full Text] [Related]

  • 7. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
    Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, Barlier A, Saveanu A.
    Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.
    Florio T, Barbieri F, Spaziante R, Zona G, Hofland LJ, van Koetsveld PM, Feelders RA, Stalla GK, Theodoropoulou M, Culler MD, Dong J, Taylor JE, Moreau JP, Saveanu A, Gunz G, Dufour H, Jaquet P.
    Endocr Relat Cancer; 2008 Jun; 15(2):583-96. PubMed ID: 18509006
    [Abstract] [Full Text] [Related]

  • 9. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.
    Ren SG, Kim S, Taylor J, Dong J, Moreau JP, Culler MD, Melmed S.
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5414-21. PubMed ID: 14602782
    [Abstract] [Full Text] [Related]

  • 10. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
    Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S.
    J Clin Invest; 1997 Nov 01; 100(9):2386-92. PubMed ID: 9410919
    [Abstract] [Full Text] [Related]

  • 11. Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro.
    Gruszka A, Culler MD, Melmed S.
    Mol Cell Endocrinol; 2012 Oct 15; 362(1-2):104-9. PubMed ID: 22705877
    [Abstract] [Full Text] [Related]

  • 12. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas.
    Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, Culler MD, Moreau JP, Enjalbert A.
    J Clin Endocrinol Metab; 1999 Sep 15; 84(9):3268-76. PubMed ID: 10487698
    [Abstract] [Full Text] [Related]

  • 13. A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies.
    Saveanu A, Morange-Ramos I, Gunz G, Dufour H, Enjalbert A, Jaquet P.
    Eur J Endocrinol; 2001 Jul 15; 145(1):35-41. PubMed ID: 11415850
    [Abstract] [Full Text] [Related]

  • 14. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas.
    Cuevas-Ramos D, Fleseriu M.
    J Mol Endocrinol; 2014 Jun 15; 52(3):R223-40. PubMed ID: 24647046
    [Abstract] [Full Text] [Related]

  • 15. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules.
    Gruszka A, Ren SG, Dong J, Culler MD, Melmed S.
    Endocrinology; 2007 Dec 15; 148(12):6107-14. PubMed ID: 17656461
    [Abstract] [Full Text] [Related]

  • 16. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro.
    Tulipano G, Bonfanti C, Milani G, Billeci B, Bollati A, Cozzi R, Maira G, Murphy WA, Poiesi C, Turazzi S, Giustina A.
    Neuroendocrinology; 2001 May 15; 73(5):344-51. PubMed ID: 11399907
    [Abstract] [Full Text] [Related]

  • 17. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr 15; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 18. Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells.
    Cuny T, Graillon T, Defilles C, Datta R, Zhang S, Figarella-Branger D, Dufour H, Mougel G, Brue T, Landsman T, Halem HA, Culler MD, Barlier A, Saveanu A.
    Pituitary; 2021 Jun 15; 24(3):351-358. PubMed ID: 33433890
    [Abstract] [Full Text] [Related]

  • 19. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
    Gatto F, Barbieri F, Gatti M, Wurth R, Schulz S, Ravetti JL, Zona G, Culler MD, Saveanu A, Giusti M, Minuto F, Hofland LJ, Ferone D, Florio T.
    Clin Endocrinol (Oxf); 2012 Mar 15; 76(3):407-14. PubMed ID: 21848909
    [Abstract] [Full Text] [Related]

  • 20. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF, Annunziato L.
    Neuroendocrinology; 2004 Mar 15; 79(3):142-8. PubMed ID: 15103227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.